Potential Benefits and Current Research Evidence Phase 2 trial data support retatrutide's efficacy for weight reduction in obesity, but 5-Amino-1MQ has no published human clinical trials and its benefits in people remain unproven
5-Amino-1MQ is a novel NNMT inhibitor that works at the epigenetic level to regulate cellular energy pathways
Injections have better bioavailability than oral supplements as they bypass the digestive system completely, providing a direct supply of B12 into the bloodstream to fuel your body
Pregnant or breastfeeding people, anyone with active cancer or a recent cancer history, anyone with liver disease, children and teenagers, and anyone with known sleep disorders should avoid 5-Amino-1MQ outside formal research supervision
Laboratory studies using 5-amino-1MQ in aged animal models have revealed that NNMT inhibition modulates many age-associated metabolic parameters, including alterations in muscle tissue metabolism and cellular stress response pathways